Related coverage linked through entity extraction aliases.
Jun 23, 2026
Duvakitug showed durable clinical and endoscopic efficacy over 44 weeks in UC and Crohn's patients in a phase 2b LTE study. The results reinforce duvakitug's potential as a best-in-class TL1A therapy. Both doses were well tolerated.
Aug 01, 2026
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
May 28, 2026
Spyre will present SPY001 topline results in ulcerative colitis on April 13, 2026. Six Phase 2 readouts are expected in 2026; Q1 net loss was $69 million.
Jul 09, 2026
Two new studies in IBD genetics show that polygenic risk scores can predict disease severity in Danish patients, and that ancestry-specific variants in Hispanic populations reveal novel risk loci and differential effects of known genes. These findings advance precision medicine by improving risk prediction and highlighting the need for diverse genetic research.
Jul 24, 2026
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
Jul 11, 2026
Takeda reported positive ENTYVIO pediatric data, secured FDA Priority Review for oveporexton, and expanded AI drug discovery. Shares trade at ¥5,609; analyst fair value is about ¥5,263.
Jul 31, 2026
Abivax aligned with FDA on obefazimod NDA strategy for ulcerative colitis, targeting filing by end‑2026. Phase 3 ABTECT data at ECCO 2026 showed early symptom relief and positive DSMB safety review. Leadership appointments support potential commercialization.
Jul 24, 2026
Celltrion released new post-hoc analysis from its phase 3 trial of Remsima SC in IBD patients at the ECCO 2026 congress. The data showed rapid clinical response after treatment gaps and maintained efficacy over 102 weeks. The company also highlighted its unique offering of infliximab in three formulations.
Jul 15, 2026
Long-term QUASAR extension data show Tremfya (guselkumab) maintained clinical and endoscopic remission in ulcerative colitis through Week 140, with 80.8% in clinical remission and no new safety signals.
Jun 13, 2026
Teva Pharmaceuticals and Sanofi reported positive Phase 2b long-term extension results for duvakitug, a TL1A-targeting monoclonal antibody, showing durable efficacy over 44 weeks in ulcerative colitis and Crohn's disease patients. UC patients achieved up to 58% clinical remission and CD patients up to 55% endoscopic response at the higher dose.
May 05, 2026
Johnson & Johnson said Tremfya met the primary endpoint in the Phase 3 FUZION study in active perianal fistulizing Crohn’s disease. At Week 24, both Tremfya dosing regimens showed statistically significant combined fistula remission versus placebo.
Apr 26, 2026
Everest Medicines launched VELSIPITY in Mainland China after NMPA approval on February 2, 2026. The first prescription was issued at The First Affiliated Hospital of Sun Yat-sen University.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Apr 19, 2026
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Apr 17, 2026
Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.
Apr 04, 2026
A study published on February 17, 2026 validated an AI workflow that predicted colorectal cancer risk in ulcerative colitis with 99% accuracy using over 55,000 patient records. The model identified low-risk and higher-risk patients from clinical notes, colonoscopy reports, and pathology findings.
Apr 05, 2026
Researchers used machine learning to identify an antimicrobial peptide, LR, that reduced inflammation and improved gut barrier function in mouse ulcerative colitis. The peptide also reshaped the microbiome and outperformed 5-aminosalicylic acid and ciprofloxacin in the model.
Mar 23, 2026
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
Mar 01, 2026
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
Mar 01, 2026
New ASCO guideline emphasizes biomarker-driven treatment for advanced gastroesophageal cancer, recommending upfront testing for HER2, PD-L1, MSI/MMR, and CLDN18.2 to guide immunotherapy and targeted therapy selection.
